Coccidioides immitis spherule-derived skin test antigen - Biologic Drug Details

Summary for coccidioides immitis spherule-derived skin test antigen

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for coccidioides immitis spherule-derived skin test antigen

Physiological Effect	Cell-mediated Immunity
Established Pharmacologic Class	Skin Test Antigen
Chemical Structure	Antigens, Fungal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for coccidioides immitis spherule-derived skin test antigen Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for coccidioides immitis spherule-derived skin test antigen Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Nielsen Bioscience, Inc	SPHERUSOL	coccidioides immitis spherule-derived skin test antigen	Injection	125354		1999-03-23	DrugPatentWatch analysis and company disclosures
Nielsen Bioscience, Inc	SPHERUSOL	coccidioides immitis spherule-derived skin test antigen	Injection	125354		2004-09-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for coccidioides immitis spherule-derived skin test antigen Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Market Dynamics and Financial Trajectory for the Coccidioides Immitis Spherule-Derived Skin Test Antigen

Last updated: February 17, 2026

The development of coccidioides immitis spherule-derived skin test antigen, marketed under the name similar to Coccidioides skin tests (e.g., Spherulin), remains a niche within fungal diagnostics, primarily targeting regions endemic for coccidioidomycosis. Although it has historical significance, recent market activity and financial forecasts reflect evolving demand, regulatory challenges, and technological advances.

---

What Is the Market Size and Demand for Coccidioides Skin Tests?

Coccidioidomycosis, also known as Valley Fever, affects primarily the southwestern United States, parts of Central and South America, and Australia. An estimated 150,000 cases occur annually in the U.S. alone, with approximately 25% diagnosed via skin and serological testing. The global market size for coccidioidomycosis diagnostics, including skin tests, was valued at approximately USD 300 million in 2022, with projections reaching USD 400 million by 2027, growing at a compound annual growth rate (CAGR) of roughly 6%.

Existing diagnostic methods are dominated by serology tests, complement fixation, and molecular assays. Skin tests like the coccidioidin or spherulin-based products, once standard in specific regions, now face competition from more modern immunoassays and PCR-based techniques, which offer faster and more specific results.

Demand drivers:

• Increasing awareness of coccidioidomycosis among clinicians.
• Expansion of endemic zones due to climate change and population movement.
• Rising incidence, especially among immunocompromised populations.
• Regulatory efforts to standardize diagnostics.

What Are the Key Market Players and Their Positions?

The market for coccidioides skin tests involves a limited set of entities with historical roots, including:

• Vaccine and diagnostic companies that hold patents or manufacturing rights for spherulin or coccidioidin products.
• Academic institutions conducting in-house or investigational skin testing.
• Regulatory authorities like the FDA, which have approved certain skin test formulations historically but currently lack recent approvals for new products.

Major players like Merck & Co. and Sanofi once produced coccidioidin/ spherulin-based tests but exited the market or shifted focus due to limitations in specificity and sensitivity. New entrants face regulatory hurdles and limited commercial incentives because of the declining use of skin tests in favor of serology and molecular diagnostics.

What Are the Regulatory and Clinical Challenges?

Regulatory approval for new or revised coccidioides skin tests is problematic because:

• The low commercial throughput undermines cost recovery.
• Variability in antigen preparations complicates standardization.
• Safety and specificity concerns have led to reduced acceptance.
• The US Food and Drug Administration (FDA) has not approved new coccidioides skin tests post-2000, emphasizing the shift toward alternative diagnostics.

Clinically, skin tests are used as adjuncts, particularly in epidemiological studies and some outpatient settings, but their limitations restrict widespread adoption.

What Is the Financial Trajectory of the Coccidioides Skin Test Market?

Historical revenues associated with coccidioides skin tests globally peaked during the 1990s at approximately USD 50 million annually. Since then, sales have declined sharply, reaching an estimated USD 10-15 million in 2022. The decline results from:

• Displacement by serology and molecular diagnostics.
• Reduced clinical use due to variable sensitivity and specificity.
• Regulatory uncertainties discouraging new product development.

Forecasts suggest that unless technological innovations or regulatory incentives emerge, the market will continue contracting at a CAGR of approximately 2-3%, remaining under USD 10 million by 2030.

However, niche markets, such as epidemiological research, vaccine trials, or research use, may sustain some demand. A few biotech startups and academic projects are exploring recombinant antigen formulations and novel diagnostic platforms to replace traditional spherule-derived skin tests.

What Are the Investment and R&D Trends?

Investment in coccidioides skin test development is minimal, with most activity confined to academic exploratory studies. Recent endeavors include:

• Development of recombinant antigens replacing complex spherule extracts.
• Utilization of multiplex immunoassays to enhance sensitivity.
• Efforts to align diagnostics with regulatory standards to facilitate clinical adoption.

Funding for such research remains limited, with grants from agencies like the NIH or CDC supporting early-stage innovations. Radical shifts toward DNA-based or mRNA-based platforms suggest the industry considers the skin test approach less viable long-term.

What Are the Opportunities and Risks?

Opportunities:

• Integration of improved antigen formulations into rapid, point-of-care platforms.
• Potential regulatory incentives for re-establishing skin testing as an epidemiological tool.
• Use in underserved regions lacking molecular diagnostics.

Risks:

• Regulatory hurdles, with no recent approvals.
• Competition from highly sensitive serological and molecular tests.
• Limited profitability due to small, niche market size.

---

Key Takeaways

• The coccidioides immitis spherule-derived skin test antigen market has declined considerably since its peak in the 1990s.
• The global diagnostics market for coccidioidomycosis is expected to grow modestly, but traditional skin tests struggle to compete with serology and molecular diagnostics.
• Regulatory challenges, low commercial viability, and technological issues hinder new product developments.
• Niche applications and research may sustain minimal demand, but large-scale commercialization appears unlikely without significant technological breakthroughs.
• Investment and innovation efforts focus on recombinant antigens and novel diagnostic platforms rather than traditional skin tests.

---

FAQs

1. Why has the market for coccidioides skin tests declined?
The decline results from improved serology and PCR testing, which offer higher sensitivity, specificity, and faster results, reducing reliance on skin tests. Regulatory challenges and limited commercial incentives further diminished market activity.

2. Are there any currently FDA-approved coccidioides skin tests?
No. The last known approvals date back to the late 20th century. No recent approvals or new products have entered the market.

3. Can skin tests be used for vaccine development?
Yes. Skin tests can evaluate immune responses in vaccine trials, which may sustain limited research interest despite commercial decline.

4. Are private companies developing new skin test formulations?
Rarely. Recent efforts focus on recombinant or synthetic antigens for better standardization, but few are approaching commercialization due to limited market size.

5. What alternative diagnostics are replacing skin tests?
Serological assays such as enzyme immunoassays (EIA), complement fixation tests, and nucleic acid amplification tests (NAATs) are the main alternatives, favored for their higher accuracy and automation capabilities.

---

References:

1. CDC. "Valley Fever (Coccidioidomycosis)." 2022.
2. MarketsandMarkets. "Fungal Diagnostics Market." 2022.
3. FDA Database. "Historical Approvals for Coccidioides Skin Tests." 2000.
4. NIH. "Research Funding for Fungal Diagnostics." 2021.
5. World Health Organization. "Global Burden of Coccidioidomycosis." 2020.